{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000213","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.905537+00:00","generated_at":"2026-05-16T11:00:10.639787+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioCryst beats FY2025 ORLADEYO rev guidance; FY2026 outlook $625-645M; Astria acquisition on track","bullets":["Preliminary unaudited FY2025 ORLADEYO net revenue $601M (+37% YoY), exceeding $590-600M guidance range.","Q4 2025 ORLADEYO net revenue $151M (+22% YoY; +36% comparable basis excl European revenue).","Cash, cash equivalents, restricted cash & investments at Dec 31, 2025: $338M.","FY2026 guidance: ORLADEYO rev $625-645M; total rev $635-660M; non-GAAP op ex $380-390M (excl Astria).","Expected close of Astria Therapeutics acquisition in Q1 2026; adds $70-80M non-GAAP op ex for navenibart Phase 3 and manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000213","json":"https://secwatch.observer/filing/0001171843-26-000213.json","markdown":"https://secwatch.observer/filing/0001171843-26-000213.md","text":"https://secwatch.observer/filing/0001171843-26-000213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326000213/0001171843-26-000213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326000213/f8k_011226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:00:10.639787+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}